U.S. Office REITs Stock News

NasdaqGS:MBX
NasdaqGS:MBXPharmaceuticals

MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge

MBX Biosciences (NasdaqGS:MBX) reported encouraging preliminary Phase 1 data for its lead obesity candidate, MBX 4291, with early weight loss signals and potential for once-monthly dosing. The company introduced a new preclinical obesity program, MBX 5765, expanding its early stage pipeline. MBX also shared positive proof-of-concept results from its Imapextide Phase 2a trial in post-bariatric hypoglycemia. These updates arrive with MBX Biosciences trading at $37.5, after a very large 1-year...